ESMO 2021: PRODIGE 24 Trial
Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
Browsing: mFOLFIRINOX
My Top 3 ASCO Abstracts by Prunella Blinman
I love a good plenary session at ASCO, and this year’s plenary session was one…
Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer
In a randomized phase III trial people with surgically removed pancreatic cancer who received mFOLFIRINOX,…